GlassScriptPhysician profile
Yinan Fu
NPI 1558897827
$1,475.41
in general payments reported to CMS, 2019-2025
19 companies · $445 in 2025
The $445 reported for 2025 was more than what a typical Pediatric Gastroenterology provider received nationally (typical 2025 total: $195).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $18.90 · 2021: $18.39 · 2022: $271 · 2023: $196 · 2024: $527 · 2025: $445.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,167.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,167.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $261.73 | 2022-2025 | Eohilia, Gattex |
| Regeneron Healthcare Solutions, INC. | $241.57 | 2023-2025 | Dupixent |
| Genzyme Corporation | $140.77 | 2023-2025 | |
| Ipsen Biopharmaceuticals, INC | $126.95 | 2024-2025 | Bylvay |
| Janssen Scientific Affairs, LLC | $118.69 | 2022 | |
| Qol Medical, LLC | $108.61 | 2023-2025 | Sucraid, Sucraid |
| Janssen Biotech, INC. | $96.02 | 2024-2025 | Tremfya, Stelara |
| Nestle Healthcare Nutrition INC. | $81.09 | 2023 | |
| Coloplast Corp | $51.75 | 2022-2024 | |
| Abbvie INC. | $50.70 | 2025 | |
| Mirum Pharmaceuticals, INC. | $42.51 | 2024 | Livmarli |
| Acadia Pharmaceuticals INC | $38.15 | 2024-2025 | Daybue |
| Mauna Kea Technologies, INC. | $24.98 | 2025 | |
| Sandoz INC. | $22.74 | 2024 | Hyrimoz |
| Olympus America INC. | $18.90 | 2020 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $18.39 | 2021 | |
| Ironwood Pharmaceuticals, INC | $16.82 | 2024 | |
| Applied Medical Technology INC | $14.25 | 2024 | |
| Travere Therapeutics, INC. | $0.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yinan Fu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.